The survival benefit was accompanied by a significant infiltration of IFNγ-, Granzyme B-, and TNFα-secreting effector T-cells, demonstrating that the combined use of CD40 agonist and PD1 antagonist antibodies can reprogram immune resistant tumors in favor of anti-tumor immunity [161]. The gene discussed is CD40; the disease is neoplasm.